



## Invitation to presentation of Acarix´s second quarter earnings report

**Acarix, a leader in acoustic and AI-based cardiac diagnostics, will publish its second quarter results on Thursday 31 August 2023 08:00 (CET). A live webcast will be held at 10 am (CEST) the same day, where President & CEO Helen Ljungdahl Round and CFO Christian Lindholm will present the report and hold Q&A, where you can ask the company questions via the form on the live page.**

The webcast will be available at <https://youtube.com/live/N9oA2JXVQRw?feature=share>

The presentation will be available after the webcast at <https://www.acarix.com/for-investors/investor-presentations>

### **For more information contact:**

Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email [helen.round@acarix.com](mailto:helen.round@acarix.com)

Christian Lindholm, CFO, phone +46 705 118333, email [christian.lindholm@acarix.com](mailto:christian.lindholm@acarix.com)

### **About Acarix**

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 8 121 576 90, [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se)) is Certified Advisor of Acarix. For more information, please visit [www.acarix.com](http://www.acarix.com).

### **Attachments**

[Invitation to presentation of Acarix´s second quarter earnings report](#)